TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 295 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $110,765 | +6.7% | 7,160 | +8.4% | 0.00% | +33.3% |
Q2 2023 | $103,812 | +24.1% | 6,608 | +30.2% | 0.00% | 0.0% |
Q1 2023 | $83,636 | +55.3% | 5,075 | +47.0% | 0.00% | +50.0% |
Q4 2022 | $53,851 | -63.4% | 3,452 | -69.6% | 0.00% | -71.4% |
Q3 2022 | $147,000 | -2.0% | 11,356 | +6.0% | 0.01% | 0.0% |
Q2 2022 | $150,000 | +3.4% | 10,716 | +6.4% | 0.01% | +16.7% |
Q1 2022 | $145,000 | +46.5% | 10,072 | +38.8% | 0.01% | +50.0% |
Q4 2021 | $99,000 | +2.1% | 7,255 | +22.7% | 0.00% | 0.0% |
Q3 2021 | $97,000 | +27.6% | 5,913 | +30.4% | 0.00% | +33.3% |
Q2 2021 | $76,000 | -12.6% | 4,536 | -4.7% | 0.00% | -25.0% |
Q1 2021 | $87,000 | +26.1% | 4,758 | +25.1% | 0.00% | 0.0% |
Q4 2020 | $69,000 | -12.7% | 3,804 | -13.6% | 0.00% | -20.0% |
Q3 2020 | $79,000 | -1.2% | 4,401 | -2.5% | 0.01% | 0.0% |
Q2 2020 | $80,000 | +110.5% | 4,514 | +80.2% | 0.01% | +66.7% |
Q1 2020 | $38,000 | -2.6% | 2,505 | +27.6% | 0.00% | 0.0% |
Q4 2019 | $39,000 | +50.0% | 1,963 | +30.1% | 0.00% | +50.0% |
Q3 2019 | $26,000 | +271.4% | 1,509 | +276.3% | 0.00% | +100.0% |
Q2 2019 | $7,000 | -78.8% | 401 | -75.3% | 0.00% | -75.0% |
Q1 2019 | $33,000 | – | 1,623 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Adelphi Capital LLP | 7,931,116 | $140,381,000 | 32.92% |
Endurant Capital Management LP | 932,967 | $16,514,000 | 6.51% |
Glenview Capital Management | 26,430,828 | $467,826,000 | 4.24% |
Paulson & Co. | 13,244,711 | $234,431,000 | 3.98% |
Blackcrane Capital, LLC | 172,955 | $3,061,000 | 3.88% |
NINE MASTS CAPITAL Ltd | 1,474,286 | $26,146,000 | 3.74% |
Velanne Asset Management Ltd | 286,640 | $5,074,000 | 3.22% |
LMR Partners LLP | 4,563,591 | $80,884,000 | 2.95% |
SECTOR GAMMA AS | 796,299 | $14,094,000 | 2.26% |
MFN Partners Management, LP | 785,000 | $13,895,000 | 2.21% |